MedWatch

Research exec on Novo's diabetes pill: "I was convinced it would get me fired"

Lars Fogh Iversen, who was recently put in charge of Novo Nordisk's internal research, has been very involved in the company's work to develop a tablet version of the GLP-1 molecule semaglutide. But when the project began more than ten years ago, it did not look very promising and it would not have happened without teamwork across the organization, he says.

Foto: Novo Nordisk/PR

When Peter Kurtzhals - Novo's Head of R&D and right hand to the Executive Vice President and Chief Science Officer at Novo Nordisk, Mads Krogsgaard Thomsen - resigned earlier this year due to health reasons after 17 years on the post, his former field of responsibility was split into two.

While the former AstraZeneca-man Marcus Schindler was put in charge of Global Drug Discovery, which mostly looks at external opportunities for Novo's R&D department, the Novo-veteran Lars Fogh Iversen was put in charge of Global Research Technologies, which mostly focuses on the internal research.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Coloplasts nye skattedetaljer viser enorme nationale forskelle - Danmark blandt de laveste skatteopkrævere

Mens Coloplast betaler godt 20 pct. i effektiv skattesats herhjemme, lægger medicoselskabet næsten 40 pct. i skatteposen af sit overskud i Frankrig, viser nye detaljerede skatteoplysninger fra virksomheden. Størstedelen af medicoselskabets ansatte arbejder i Ungarn, hvor firmaet også betaler den laveste selskabsskat på bare 15 pct, men produktionen er lagt i landet af en række andre årsager, fortæller Coloplast.

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier